Jacob Schachter
Overview
Explore the profile of Jacob Schachter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
155
Citations
12160
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Stoff R, Asher N, Laks S, Steinberg Y, Schachter J, Shapira-Frommer R, et al.
Front Oncol
. 2023 Jun;
13:1180988.
PMID: 37274272
Introduction: Immunotherapy has revolutionized the prognosis of patients with metastatic melanoma. To date, the most active regimen is the combination of ipilimumab + nivolumab (ipi-nivo) achieving a response rate of...
12.
Markovits E, Harush O, Baruch E, Shulman E, Debby A, Itzhaki O, et al.
Cancer Immunol Res
. 2023 Apr;
11(7):909-924.
PMID: 37074069
Immunotherapy has revolutionized the treatment of advanced melanoma. Because the pathways mediating resistance to immunotherapy are largely unknown, we conducted transcriptome profiling of preimmunotherapy tumor biopsies from patients with melanoma...
13.
Ascierto P, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, et al.
Lancet Oncol
. 2022 Dec;
24(1):33-44.
PMID: 36460017
Background: Primary analysis of the phase 3 IMspire150 study showed improved investigator-assessed progression-free survival with first-line atezolizumab, vemurafenib, and cobimetinib (atezolizumab group) versus placebo, vemurafenib, and cobimetinib (control group) in...
14.
Stoff R, Grynberg S, Asher N, Laks S, Steinberg Y, Schachter J, et al.
Front Oncol
. 2022 Nov;
12:1020058.
PMID: 36419899
Introduction: Immunotherapy has revolutionized metastatic Melanoma therapy. The most active regimen is combination therapy of Ipilimumab-Nivolumab (Ipi-Nivo) with response rates (RR) of ~60% and median overall survival (OS) of ~6...
15.
Grynberg S, Stoff R, Asher N, Shapira-Frommer R, Schachter J, Haisraely O, et al.
Ther Adv Med Oncol
. 2022 Nov;
14:17588359221131521.
PMID: 36339927
Introduction: Uveal melanoma (UM) is a subtype of melanoma arising from the ocular region. Despite various local therapies available, a significant portion of patients develop distant metastases, primarily to the...
16.
Weber J, Schadendorf D, Del Vecchio M, Larkin J, Atkinson V, Schenker M, et al.
J Clin Oncol
. 2022 Sep;
41(3):517-527.
PMID: 36162037
Purpose: Ipilimumab and nivolumab have each shown treatment benefit for high-risk resected melanoma. The phase III CheckMate 915 trial evaluated adjuvant nivolumab plus ipilimumab versus nivolumab alone in patients with...
17.
Mor E, Laks S, Assaf D, Asher N, Ben-Betzalel G, Grynberg S, et al.
Surg Oncol
. 2022 Aug;
44:101808.
PMID: 35932622
Background: Metastatic spread of malignant melanoma to the abdomen presents a therapeutic challenge. Targeted and Immune-therapies dramatically improve patients' survival, yet some patients may still benefit from surgical intervention. This...
18.
Babiker H, Borazanci E, Subbiah V, Agarwala S, Algazi A, Schachter J, et al.
Clin Cancer Res
. 2022 Aug;
28(23):5079-5087.
PMID: 35917516
Purpose: Tilsotolimod is an investigational synthetic Toll-like receptor 9 (TLR9) agonist that has demonstrated antitumor activity in preclinical models. The ILLUMINATE-101 phase I study explored the safety, dose, efficacy, and...
19.
Schachter J, Ajayi A, Nguyen P
J Couns Psychol
. 2022 Jun;
69(5):732-744.
PMID: 35737540
The COVID-19 pandemic has not only accounted for a substantial number of deaths in the United States but also deleterious mental health outcomes. We integrated multiple lines of previous research...
20.
Margolis N, Moalem H, Meirson T, Galore-Haskel G, Markovits E, Baruch E, et al.
Cancer Immunol Res
. 2022 Jun;
10(9):1127-1140.
PMID: 35731225
The effect of tumor/T-cell interactions on subsequent immune infiltration is undefined. Here, we report that preexposure of melanoma cells to cognate T cells enhanced the chemotaxis of new T cells...